PME share price is in focus.
Founded in 1983, Pro Medicus is a provider of radiology IT software serving hospitals, imaging centers and healthcare groups worldwide.
The company’s product portfolio focuses on radiology information systems (RIS), picture archiving and communication systems (PACS) and advanced visualization solutions. These tools support tasks ranging from patient scheduling and billing to rapid medical imaging interpretation and analysis.
ProMedics’ key value proposition lies in its flagship Visage software, which enables radiologists to remotely view large image files generated by X-rays on mobile devices. This capability allows diagnostic decisions to be made on the go, potentially improving patient outcomes by providing timely and accessible information.
Key metrics
For investors, PMEK Revenue, Gross Marginand profit Can provide valuable insight into company performance.
PME last reported annual revenue of $162m with a Compound Annual Growth Rate (CAGR) 33.4% per annum over the last 3 years. While the absolute number is useful to know, the key point is this. trend. We want to see consistent, upward momentum in earnings.
Gross margin measures profitability before overhead costs are taken into account – it reflects the strength of a company’s core business operations. PME’s latest reported gross margin stood at 99.8%.
Finally, the number we’re most interested in – profit. In the last fiscal year, ProMedics Limited reported a profit of $83 million. Three years ago they made a profit of $31m, representing a CAGR of 39.0%.
Financial health of PME shares
Profit is important, but just as important Capital Health of the company. We want to know about a company’s leverage, their ability to service debt, and their ability to generate a return on assets. A scale that we can see. Net debt. It is simply the total debt minus the company’s cash holdings.
Pro Medicus Ltd’s net debt is currently -$153m. A negative value here indicates that the company has more assets than debt, suggesting that the PME is in a strong financial position.
Another figure we can see is Debt/Equity Percentage. This tells us how much debt the company has compared to shareholder equity – also known as leverage. PME has more equity than debt, with a debt/equity ratio of 1.1%.
Finally, we can see Return on Equity (ROE). ROE tells us how efficiently the company is converting shareholder equity into profits – a high number suggests the company is creating a lot of value for investors, while a low number raises concerns that capital is not necessarily being allocated efficiently. PME generated an ROE of 50.7% in FY24.
What to make of PME shares?
With strong revenue growth over the past 3 years, profits trending upward, and solid ROE, the PME share price could be worth watching in 2025.
Please keep in mind that this should only be the beginning of your research. The quality of the company is one thing, but making sure the valuation is reasonable is another. There are many ways you can try to value a company. If you want to learn more about share price evaluation, you can sign up for one of our many free online investing courses.
